(P040) Hyperbaric Oxygen Treatment for Reducing Side Effects of Breast Radiation Therapy
Hyperbaric oxygen treatment is a well-tolerated treatment for delayed radiation injuries of breast cancer patients. Side effects are minimal and reversible. Patient-reported outcomes for patients receiving hyperbaric oxygen treatment are positive.
David N. Teguh, MD, PhD, Albert van den Brink, MD, Rob A. van Hulst, MD, PhD; Academic Medical Center, University of Amsterdam
BACKGROUND/PURPOSE: To examine patient-reported outcomes (PROs) of breast cancer patients managed with hyperbaric oxygen treatment (HBOT) for side effects of radiation in a university hospital. HBOT is a therapy used for delayed radiation injuries (DRIs). HBOT improves oxygenation of the tissues and promotes formation of collagen matrix and angiogenesis by administering 100% oxygen to patients under increased pressure of 2.4 atmospheres absolute (ATA). Published literature regarding HBOT and DRIs of the breast is still scarce.
METHODS: Breast cancer patients treated with HBOT were invited to complete quality of life questionnaires using European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23, Numeric Rating Scale (NRS-11), and Patient Global Impression of Change (PGIC) (2014). HBOT consisted of an average of 40 sessions, 5 days per week. In total, 80 minutes of 100% O2 was delivered during a 115-minute hyperbaric session.
RESULTS: A total of 29 patients were available for evaluation. Regarding the 29 patients receiving the questionnaires, mild to no complaints were seen regarding “pain in arm” (59%), “swollen arm” (79%), “arm movements” (72%), “painful area” (76%), “swollen area” (83%), “oversensitive area” (72%), “skin problems” (79%), NRS-11 (63%), and PGIC (85%).
CONCLUSIONS: HBOT is a well-tolerated treatment for DRIs of breast cancer patients. Side effects are minimal and reversible. PROs for patients receiving HBOT are positive-on average, 70% to 80% experience mild to no complaints of DRIs. A prospective trial exploring the optimal time frame of hyperbaric treatment is warranted and will be undertaken at our university center.
Proceedings of the 98th Annual Meeting of the American Radium Society -americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
